Register free for our breaking news email alerts with analysis and cutting edge commentary from our award winning team. Registration only takes a minute.

GAM Multistock - Health Innovation Eq-USD B

Ranked 1 out of 2 in - Pharmaceuticals & Health Care over 12 months
All calculations are in EUR unless stated

Managed by

Christophe Eggmann

Christophe Eggmann is Portfolio Manager of the JB Health Innovation Fund. He joined GAM Group in November 2010. Prior to that, he held various positions as a fund manager and equity analyst at Bank Hofmann, Rothschild Bank and Credit Suisse. Christophe Eggmann holds a Master in Business Administration and Economics from the University of Neuchâtel and is a CFA Charterholder. He is based in Zurich.

Objective

The fund seeks to achieve long-term capital growth by investing globally in innovation-driven companies active in all health-care sub-sectors (pharmaceuticals, biotechnology, health-care services & supplies, medical technology, specialty pharmaceuticals and generics). The Fund is suitable for equity investors with a long-term horizon and appropriate risk awareness who wish to complement their portfolio with a concentrated investment in the health-care sector.

Showing fund performance in Lithuania View performance globally

Performance

Pharmaceuticals & Health Care over : 31/03/2017 - 31/03/2018
  • Rank 1/2 Total Return
  • Rank 2/2 Standard Deviation
  • Rank 2/2 Max Drawdown
Fund Name Currency Return
1 GAM Multistock - Health Innovation Eq-USD B EUR

-3.7%

2 SEB Medical EUR

-8.1%

Total Return

Quarterly Performance

to 31/03/2018 Annual Q1 Q2 Q3 Q4
2018 -2.0%
2017 10.0% 12.0% -0.4% 0.1% -1.4%
2016 -15.4% -19.7% 6.2% -0.7% -0.1%
2015 21.5% 26.6% 1.1% -15.1% 11.8%
2014 50.6% 7.9% 8.4% 14.9% 12.1%
2013 57.3% 17.6% 8.2% 19.0% 3.9%
2012 25.0% 13.5% 10.1% 9.5% -8.7%
2011 15.2% -0.3% 2.5% -3.5% 16.8%
2010 18.3% 18.1% -7.4% 0.2% 8.0%
2009 1.1% 0.6% 0.2% 1.2% -1.0%
2008 2.0% 16.0% -11.1%

Month by Month Performance

Returns Vs Risk

Registered For Sale In

  1. Austria
  2. Belgium
  3. Bulgaria
  4. Denmark
  5. Estonia
  6. Finland
  7. France
  8. Germany
  9. Iceland
  10. Italy
  11. Latvia
  12. Liechtenstein
  13. Lithuania
  14. Luxembourg
  15. Netherlands
  16. Norway
  17. Singapore
  18. Spain
  19. Sweden
  20. Switzerland
  21. United Kingdom

Fund Info

  • Launch date31/01/2008
  • Share Class size96Mn
  • Base currencyUSD
  • ISIN LU0329426950

Purchase Info

  • Min. initial investment0
  • Min. regular additional investment0

Charges

  • Annual management1.60%

Related News

Pfizer power play: healthcare stars react to $14bn deal

Citywire Selector canvassed sector specialists on what the pharma giant’s latest purchase means for M&A and long-term investments.

Pfizer & Allergan's abandoned mega-merger: what happens next

As pharmaceutical giant halts its merger with Allergan, Citywire Selector asked if the sector had cracked its M&A addiction.

Health scares: GAM star Eggmann on the mad year for the sector

Citywire AA-rated Christophe Eggmann on how innovation, major corrections and revolutionary treatments are proving healthy bets for his strategy.

US Treasury can’t restrain M&A boom, says healthcare star

VIDEO: AAA-rated Christophe Eggmann thinks Pfizer will buy Allergan despite authority's plans to stop tax-inversion deals.

Healthcare M&A is scaring investors, says GAM star

Citywire AA-rated healthcare specialist Christophe Eggmann thinks a number of business models in the industry are only focused on price hikes.

Double manager hire for Pictet’s healthcare team

Swiss asset management group raids rival firms for two new managers in order to help add coverage in specialist sectors.

Healthcare manager to depart Swiss & Global AM

Sector specialist set to end six year stint with Zurich-based asset management group later this month.

Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in the currency and currencies indicated).